1. Home
  2. ALLO vs FC Comparison

ALLO vs FC Comparison

Compare ALLO & FC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • FC
  • Stock Information
  • Founded
  • ALLO 2017
  • FC 1983
  • Country
  • ALLO United States
  • FC United States
  • Employees
  • ALLO N/A
  • FC N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • FC Other Consumer Services
  • Sector
  • ALLO Health Care
  • FC Consumer Discretionary
  • Exchange
  • ALLO Nasdaq
  • FC Nasdaq
  • Market Cap
  • ALLO 277.8M
  • FC 289.1M
  • IPO Year
  • ALLO 2018
  • FC 1992
  • Fundamental
  • Price
  • ALLO $1.21
  • FC $22.10
  • Analyst Decision
  • ALLO Strong Buy
  • FC Buy
  • Analyst Count
  • ALLO 9
  • FC 1
  • Target Price
  • ALLO $8.44
  • FC $35.00
  • AVG Volume (30 Days)
  • ALLO 2.5M
  • FC 126.2K
  • Earning Date
  • ALLO 08-06-2025
  • FC 07-02-2025
  • Dividend Yield
  • ALLO N/A
  • FC N/A
  • EPS Growth
  • ALLO N/A
  • FC N/A
  • EPS
  • ALLO N/A
  • FC 0.81
  • Revenue
  • ALLO N/A
  • FC $279,943,000.00
  • Revenue This Year
  • ALLO N/A
  • FC N/A
  • Revenue Next Year
  • ALLO $199.63
  • FC $5.25
  • P/E Ratio
  • ALLO N/A
  • FC $27.19
  • Revenue Growth
  • ALLO N/A
  • FC N/A
  • 52 Week Low
  • ALLO $0.86
  • FC $18.94
  • 52 Week High
  • ALLO $3.78
  • FC $44.46
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 43.73
  • FC 43.89
  • Support Level
  • ALLO $1.11
  • FC $22.28
  • Resistance Level
  • ALLO $1.29
  • FC $24.06
  • Average True Range (ATR)
  • ALLO 0.09
  • FC 1.02
  • MACD
  • ALLO -0.01
  • FC 0.03
  • Stochastic Oscillator
  • ALLO 25.81
  • FC 26.97

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About FC Franklin Covey Company

Franklin Covey Co is a company focused on organizational performance improvement. It focuses on providing time management and effectiveness training for individuals and corporations via online training as well as in-person workshops and events. The company provides training and consulting services in the areas of leadership, execution, productivity, trust, sales performance, customer loyalty, and educational improvement. It operates in the business segments of Direct Offices, Education division, and International Licensees. The company derives revenue from providing training and consulting services, and through the selling of books, audio media, and other related products. It has a business presence in the Australia, New Zealand, China, Japan, United Kingdom, Ireland, and Other countries.

Share on Social Networks: